Trusted Resources: Education
Scientific literature and patient education texts
Small Bowel Amyloidosis
source: Current Gastroenterology Reports
year: 2018
authors: Bansal R, Syed U, Walfish J, Aron J, Walfish A
summary/abstract:Purpose of Review:
The goal of this paper is to review the literature on small bowel amyloidosis. Our review focuses on the underlying etiology, histopathology, clinical features, endoscopic and radiologic findings, and the mainstay of management.
Recent Findings:
The latest research shows changing epidemiological trends of different types of amyloidosis. It also reveals a better understanding of its pathophysiology and shows improvement in treatment outcomes. Amyloidosis is a group of diseases of multiple etiologies and clinical presentations. It is characterized by pathological deposition of insoluble fibrillar proteins within various organs leading to disruption of their structure and function. The classification of amyloidosis includes primary, secondary, dialysis-related, senile, and hereditary. Amyloidosis can be systemic or localized. The incidence of AA amyloidosis is declining in frequency. If the gastrointestinal (GI) tract is involved, the small intestine is the most commonly affected site. Overall, outcomes among patients with newly diagnosed amyloidosis have improved. This article focuses on small bowel amyloidosis.
organization: Icahn School of Medicine at Mount Sinai, USA; NYU Langone Health, USADOI: 10.1007/s11894-018-0616-y
read more full text
Related Content
-
ISA 2020 | Burning Questions: ASCT in AL Amyloidosishttps://www.youtube.com/watch?v=KmcLvnXC...
-
Hereditary ATTR Amyloidosis: Burden of Illness and Diagnostic ChallengesHereditary transthyretin-mediated (hATTR...
-
Genetic Counseling for Hereditary TTR Amyloidhttps://www.youtube.com/watch?v=w97DLzdt...
-
Hereditary Transthyretin AmyloidosisClinical characteristics. Hereditary tr...
-
Larry Anderson, MD, PhDLarry Anderson is Associate Professor ...
-
Chafic Karam, MDDr. Chafic Karam is a Neurologist at the...
-
Alnylam Announces 3-Month Extension of Review Period for New Drug Application for VutrisiranAlnylam Pharmaceuticals, Inc., the leadi...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.